Category Press Releases

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to…

Advent International and Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced the completion of their previously…

Bausch + Lomb Completes Acquisition of XIIDRA Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a…

Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®) platform, along with Prof. Lukas Jeker’s team at the Department…

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart…

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the Phase 3 CheckMate -77T trial met its primary endpoint of…

Biocytogen officially launches the RenMice Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice ® ​​series , which includes a collection of independently developed fully human antibody mice and TCR mice with proprietary intellectual property. The term “Ren”, defined as “human”,…

Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, today announced that it has raised $273 million in…

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies to eliminate mesothelioma and other diseases, was part of a…

Dr. Patrick Fox Named President of Amerigroup New Jersey Amerigroup New Jersey, a wholly owned subsidiary of Elevance Health and one of New Jersey’s largest coordinators of Medicaid managed care benefits, announced today that Patrick K. Fox, M.D., a New…

Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer  Roche announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a…

AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday, Sept.…